Related Experiment Videos
When should triptans be taken during a migraine attack?
1Department of Neurology, University of Liège, CHR Citadelle, Liège, Belgium. jschoenen@ulg.ac.be
CNS Drugs
|August 29, 2001
Summary
Treating mild migraine attacks with triptans early may improve effectiveness. Current recommendations to delay triptan use are based on trial protocols, not clinical evidence, and may hinder optimal migraine management.
Area of Science:
- Neurology
- Pharmacology
Background:
- Acute migraine treatment strategies traditionally involve early intervention.
- Triptan use in clinical trials typically delays administration until moderate headache intensity.
- This delay may stem from trial protocols and cost-reduction attempts rather than proven efficacy.
Purpose of the Study:
- To evaluate the efficacy of early triptan administration for mild migraine attacks.
- To challenge the conventional recommendation of delaying triptan intake.
Main Methods:
- Review of existing literature and retrospective analyses of controlled trials.
- Examination of data from 'protocol violators' in sumatriptan trials.
- Analysis of comparative efficacy against other acute treatments.
Main Results:
- Retrospective analyses suggest sumatriptan is more effective when taken during mild headache phases.
- Early treatment potentially increases pain-free responses and therapeutic gains.
- Evidence indicates triptans may be beneficial even for mild headaches resembling tension-type headaches.
Conclusions:
- The current practice of delaying triptan intake is not strongly supported by evidence.
- Further randomized controlled trials are needed to confirm efficacy in mild migraine.
- There is no apparent medical contraindication to using triptans for mild headaches within recommended weekly limits.